Congress Eyes Review of Rapidly Rising Drug Costs
Congress will likely resume looking into the issue of rapidly rising drug costs following release of a Government Accountability Office (GAO) report that prices of more than 400 brand name drugs increased by at least 100% between 2000 and 2008. These 416 brand name drug products represented 321 different drug brands.
More than half of the brand name drug products that had large price increases were in three therapeutic classes: central nervous system, anti infective, and cardiovascular. These therapeutic classes include drugs used to treat conditions, such as fungal or viral infections, and heart disease.
Almost half of the price increases were for brand name drug products purchased from drug manufacturers or wholesalers, repackaged, and resold in smaller packages to healthcare providers. In 2008, the prices for 71 drug products increased by 100%, but in 2000, only 28 drug product prices increased by that amount.
However, some drug repackagers serve a niche in the drug market—claiming a small share of the market in a therapeutic class. Some of the higher price increases were for drugs priced less than $25 per unit. A full course of treatment for some of these drugs could total several thousand dollars, GAO said.
Based on interviews with experts and industry representatives, a lack of therapeutically equivalent drugs—both generics and other brand name drugs used to treat the same condition—plus limited competition may contribute to the high price increases. Also, the limited availability of therapeutically equivalent drugs may result from patent protection and market exclusivity, along with the size of the market for a given drug.
"It is hard to find a good faith explanation for price increases that are this severe, said Sen. Charles Schumer (D-NY), who along with Sen. Amy Klobuchar (D-MN), had requested the GAO investigation following a 1998 hearing. "This report will lead to a strong demand for action by Congress. We should make sure Medicare is allowed to negotiate drug prices in the final version of the healthcare bill."
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- CA Fines 8 Hospitals for Medical Errors
- Centralizing the Revenue Cycle Protects the Bottom Line
- Revenue Cycles Get a Boost from Simple JPEG Files
- IOM Identifies GME Problems, Calls for Finance Changes
- Employers Weigh Risks, Benefits of Private Exchanges
- Doctors Feel Pressure to Accept Risk-based Reimbursement